FDMT Stock Analysis: Buy, Sell, or Hold?
FDMT - 4D Molecular Therapeutics, Inc. Common Stock
$11.91
1.48 (14.25%)
▲
5d:
+29.12%
30d:
+37.0%
90d:
+28.98%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When FDMT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: FDMT is 20.1% above its trading range ($9.91). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: FDMT is 20.1% above its trading range ($9.91). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: FDMT is currently trading at $11.90, which is considered extended relative to its 30-day fair value range of $8.45 to $9.91.
Technical Outlook: Technically, FDMT is showing sideways momentum. The price is approaching resistance at $11.73. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 14.3% recently.
Market Sentiment: FDMT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $28.22 (+170.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FDMT is showing sideways momentum. The price is approaching resistance at $11.73. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 14.3% recently.
Market Sentiment: FDMT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $28.22 (+170.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.45 -
$9.91
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+20.1% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+14.3%)
- BULLISH: Trading 170.8% below Wall St target ($28.22)
- WARNING: Recommendation downgraded due to 20.1% overvaluation
Trading Range Analysis
30-Day Trading Range
$8.45 -
$9.91
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$8.37
Resistance Level
$11.73
Current Trend
Sideways
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.80
Wall Street Target
$28.22
(+170.8%)
Revenue Growth (YoY)
21664.3%
Profit Margin
-182.3%
Share & Embed Analysis
Last updated: June 23, 2026 2:04 PM ET
Data refreshes hourly during market hours. Next update: 3:04 PM
Data refreshes hourly during market hours. Next update: 3:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FDMT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Ashoo Gupta
SELL
390 shares
2026-03-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 57 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
12 analysts |
$139 | 65 BUY |
